Kura Oncology (KURA) Current Deferred Revenue (2024 - 2026)

Kura Oncology (KURA) has 3 years of Current Deferred Revenue data on file, last reported at $47.7 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 16.79% year-over-year to $47.7 million in Q1 2026; TTM through Mar 2026 was $47.7 million, a 16.79% increase from a year earlier, with the FY2025 full-year figure at $49.0 million, up 101.82% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $47.7 million, down from $49.0 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for KURA reached as high as $49.4 million in Q2 2025 and fell as low as $24.3 million in Q4 2024.
• Historically, Current Deferred Revenue has averaged $43.3 million across 3 years, with a median of $48.2 million in 2025.
• Across the five-year window, Current Deferred Revenue soared 101.82% in 2025 and grew 16.79% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $24.3 million in 2024, then jumped by 101.82% to $49.0 million in 2025, then decreased by 2.61% to $47.7 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $47.7 million in Q1 2026, $49.0 million in Q4 2025, and $48.8 million in Q3 2025.